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Abstract  
Following IFRS mandatory adoption in 2005, the criteria determining the accounting 
treatment of R&D expenditure have changed for UK listed companies that publish 
consolidated financial statements. Therefore, recent literature raises concerns about 
the value relevance of R&D assets and expenses in the UK, after 2005. Using very 
recent data, we respond to these calls for research. Adding to the absence of prior 
evidence regarding the pre-IFRS period, we find that the capitalised portion of R&D 
is significantly positively related to market values, suggesting that the market 
perceives these items as successful projects with future economic benefits. R&D 
expenses are significantly negatively related to market values under IFRS, 
supporting the proposition that they reflect no future economic benefits and thus they 
should be expensed. Also in contrast with evidence regarding the pre-IFRS period, 
R&D expenses are negatively value relevant only for large companies. Accordingly, 
we argue that transition to IFRS does have implications on the valuation of R&D 
expenditure in the UK.  
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I. Introduction 
Depending on the accounting standards in place, Research and Development (R&D) 
expenditure can either be expensed as incurred as a whole or partly capitalised and 
partly expensed. The rationale behind the capitalisation is that significant future 
economic benefits are expected to be generated, meeting the criteria for asset 
recognition (Lev et al., 2002). The rationale for charging the R&D expenditure to the 
income statement is that such benefits are rather uncertain.  
 UK General Accepted Accounting Principles (GAAP) permits the 
capitalisation of certain R&D expenditure. More specifically, the Statement of 
Standard Accounting Practice (SSAP) 13, Accounting for Research and 
Development, provides discretion with regard to capitalisation of certain R&D 
expenditure when the recognition criteria are met (paragraph 25). However, it is 
noted that, since 2005, all European Union (EU) publicly traded firms are required to 
prepare consolidated accounts under International Financial Reporting Standards 
(IFRS)1
The requirements of IAS 38 for the capitalisation of R&D expenditure are 
generally similar with those of the UK GAAP with only one subtle but important 
difference. Capitalisation of certain R&D expenditure is a result of the standard’s 
requirements and not management’s matter of choice. The exercise of discretion to 
capitalise certain R&D expenditure is constrained. In contrast, if a series of specific 
criteria are met, a company should capitalise the R&D expenditure as an asset.  
 and as a consequence the requirements of IAS 38 Intangibles Assets should 
be followed instead.  
This difference is expected to result in significant valuation implications 
because capitalisation of R&D in the UK was rare prior to 2005 (Green et al., 1996; 
                                                 
1 In some jurisdictions (e.g. Greece and Italy), this requirement applies also to listed companies which 
publish only individual accounts.  
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Stark and Thomas, 1998; Oswald, 2008). Considering this, along with evidence from 
Australia (cf. Wyatt, 2008), Stark (2008, p. 279) argues that ‘... the IAS, in removing 
discretion over the treatment of development expenditures, remove a useful way for 
firms to communicate information to the stock markets’ (with reference to the 
findings of Oswald (2008), see below).  
Following along these lines, the first objective of this paper is to examine 
whether the R&D reported assets and expenses are value relevant after the adoption 
of IFRS in the UK. Further, in contrast with evidence from the US, Shah et al. (2008, 
p. 90) indicate that prior to 2005 there was ‘no clear-cut size [valuation] advantage 
of large firms over small firms’ as far as R&D was concerned in the UK. Therefore, 
our second objective is to examine any size-related valuation consequences of R&D 
after IFRS mandatory implementation in the UK.  
To pursue these objectives, we use recent data by focusing on the financial 
years 2005 to 2007 of companies with R&D activity, as this is indicated in the 2006, 
2007, and 2008 ‘R&D Scoreboards’.2
On that basis, we contribute to the existing literature by adding an empirical 
study examining the value relevance of R&D assets and expenses after the 
mandatory transition to IFRS in the UK, where companies are required to assess 
whether the capitalisation criteria are met compared to the discretion available in the 
past. To the best of our knowledge this is the first study to address this issue. 
 We do find that the capitalised portion of 
R&D is positively related to market values, with no significant differences across 
large and small firms. We also find that the expensed portion of R&D is negatively 
related to market values. Yet, this finding is applicable to large companies only.  
The remainder of the paper is organised as follows. Section II provides the 
                                                 
2 The Scoreboards were published by the Department of Innovation, University and Skills (hereafter 
DIUS; currently named as Department for Business Innovation and Skills). The 2009 Scoreboard had 
not been published at the time of data collection. 
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background to the accounting of R&D expenditure in the UK over the last 30 years 
and reviews prior literature. This discussion leads to the development of the research 
hypotheses. Section III describes the research design and the data employed. Section 
IV reports the empirical findings. Section V forms the concluding remarks. 
 
II. Background and Development of Hypotheses 
R&D reporting in the UK: UK GAAP vs. IFRS 
SSAP 13 was originally issued in 19773. While it introduced the requirement for all 
the expenditure incurred at the research stage to be expensed as incurred, it also 
introduced the option to capitalise certain R&D expenditure, providing that certain 
criteria which indicate the capitalisation of R&D are met. SSAP 13 was revised in 
1989, with no major changes,4
The criteria for R&D capitalisation are the following: the project is clearly 
defined with the related expenditure being separately identifiable; the project is 
technically viable and commercial viable; adequate resources exist to complete the 
project; and lastly, all related expenditures are more than covered from the related 
revenues (paragraph 25). It is notable that, despite the provision of the optional 
capitalisation, R&D expenditures were mainly expensed as incurred (Green et al., 
1996) and it was rather rare for companies to capitalise any portion of R&D (Stark 
and Thomas, 1998; Oswald, 2008). 
 and continues to provide an option to capitalise 
certain R&D expenditure when the recognition criteria are met (paragraph 25).  
                                                 
3 It was the outcome of two exposure drafts (ED): ED 14 (1975) and ED 17 (1976). Hope and Gray 
(1982) as well as Elliot and Elliot (2006, p. 450) discuss the background to SSAP 13. 
4 One of the changes introduced was to recommend companies which meet certain size criteria to 
disclose R&D expenditure. In particular, paragraph 19b states that companies are required to disclose 
the amount expensed by distinguishing the current year’s expenditure and the amortised amount from 
deferred expenditure. This is applicable to all ‘public limited companies, or special category 
companies, or subsidiaries of such companies, or [the companies] which exceed by the multiple of 10 
the criteria for defining medium-sized company under Companies Act 1985’ (paragraph 20). 
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However, since 2005, all EU publicly traded firms reporting consolidated 
financial statements adopted IFRS, with IAS 38 Intangible Assets governing the 
accounting treatment of intangibles. IAS 38 requires the capitalisation of certain 
R&D expenditures which meet the following criteria. In order to capitalise the 
development costs an enterprise should assess: the technical feasibility of the 
intangible asset; the intention to complete the asset with the ability to sell (or use) it; 
the availability of resources, technical or financial, to complete it; the ability to 
reliably measure the expenditure and the ability to justify that the asset will generate 
future economic benefits (paragraph 57). Similar to SSAP 13 (1986), research 
expenditure should be expensed as incurred. 
At first glance, it appears that the treatment of R&D expenditure is very 
similar under UK GAAP and IFRS. However, there is a subtle but important 
difference: IFRS requires the capitalisation of the R&D expenditure meeting the 
specified criteria, contrary to the UK GAAP which provides an option to capitalise 
the R&D expenditure which meets the criteria. Thereby, following the transition to 
IFRS, management’s discretion would be constrained. As a result, several companies 
would have to capitalise certain R&D expenditure previously expensed as incurred 
(cf. Green et al., 1996; Stark and Thomas, 1998; Oswald, 2008). 
 
Literature Review and Hypotheses 
Among the earliest studies to examine the revised SSAP 13 (1989) was that of Green 
et al. (1996). Using a sample of firms for the period 1990 to 1992, they regress the 
companies’ market values against book value of equity, R&D expense and residual 
income.5
                                                 
5 They measure residual income as earnings before R&D expense less the product of cost of equity 
 Their findings suggest that, on average, the R&D expense has a positive 
 5 
 
A
ppendices 
statistically significant relationship with market values. They interpret this result as 
the market perceives R&D expense as a capital expenditure i.e. the market reverses 
the expensed R&D.  
Further, Stark and Thomas (1998) employ a sample of companies for the 
period 1990 to 1994. In contrast to Green et al. (1996), they regress companies’ 
market values against earnings before extraordinary and exceptional items (instead 
of utilising residual income). Nevertheless, their results are similar with those 
obtained from Green et al. (1996). The R&D expense is perceived as a capital 
component (i.e. asset) instead of being treated as any other expense. In a similar 
vein, although the focus of the study is not on R&D expenditure per se, Akbar and 
Stark (2003) report results of similar significance with respect to R&D expense. For 
the period 1990 to 2001 they report a significantly positive coefficient for R&D 
expense.6
Contrary, Zhao (2002) focuses only on companies that capitalise a portion of 
R&D and examines the value relevance of R&D reporting in France, Germany, UK 
and USA for the period 1990 to 1999. The key characteristic of this study is that it 
examines both the value relevance of R&D assets and R&D expenses in the UK. 
Interestingly, Zhao’s (2002) results show that the capitalised portion of R&D has a 
negative coefficient, although it is statistically insignificant. This is possibly a result 
 Focusing almost on the same period (1990 to 1998), Shah et al. (2009) 
report similar results to Akbar and Stark (2003). Additionally, Shah et al. (2008) 
examine the value relevance of the R&D expense focusing on the period 1998 to 
2002 and, consistent with the findings of prior research, they find that R&D expense 
is positively value relevant.  
                                                                                                                                          
capital and lagged book value of equity. 
6 The consistent evidence in the UK that R&D expenses are perceived as capital components is in line 
with evidence in the US (e.g. Lev and Sougiannis, 1996; Aboody and Lev, 1998; Healy et al., 2002 
Lev et al., 2002; Ballester et al., 2003; Xu et al., 2007) and elsewhere (e.g. Han and Manry, 2004).  
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of the small proportion of companies capitalising R&D in the sample under 
examination (11%).7 Additionally, R&D expense is negatively value relevant i.e. it 
has a negative and significant coefficient.8
Further, Oswald (2008) examines the value relevance of R&D by 
distinguishing the companies which capitalise a portion of the R&D expenditure 
(‘capitalisers’) from those expensing all the related expenditure (‘expensers’). It is 
worth noting that similar to Zhao (2002) only a small portion of the sample 
employed consists of ‘capitalisers’ (approximately 14.5%) which is consistent with 
the evidence of the prior literature (cf. Green et al., 1996; Stark and Thomas, 1998; 
Zhao, 2002).
  
9
Drawing on the above summary of findings, evidence with respect to the 
value relevance of R&D reporting in the UK is limited to R&D expense. This is, 
presumably, because of the discretion provided to companies by SSAP 13 to 
capitalise certain R&D expenditure, resulting in capitalisation in the UK to be rare. 
The fact that capitalisation is rare explains the evidence in the prior literature that 
R&D expense is treated as a capital component (i.e. positive coefficient).  
 After adjusting ‘capitalisers’ to as if ‘expensers’ and ‘expensers’ to as 
if ‘capitalisers’, he compares the value relevance for both actual and adjusted figures 
for the two groups separately. He finds that for both groups the value relevance of 
adjusted figures is not significantly different from the value relevance of the actual 
figures. For this reason, Oswald (2008) concludes that ‘managers choose the correct 
method for accounting for R&D’ (ibid, p. 22).  
As discussed above, following transition to IFRS, management’s discretion 
                                                 
7 Studies in other countries illustrate that the capitalised portion of R&D is positively value relevant 
(cf. Han and Manry, 2004; Ahmed and Falk, 2006) consistent with the premise that it represents 
future economic benefits. 
8 Although this result appears to contradict with prior evidence in the UK as discussed above, this 
may not be the case. Other studies do not take into consideration the capitalised portion of R&D 
which actually reflects expected economic benefits by the companies. 
9 Although the focus of their research is different, Osma and Young (2009) report similar information.  
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would be constrained and as a result several companies would have to capitalise 
certain R&D expenditure previously expensed as incurred (cf. Green et al., 1996; 
Stark and Thomas, 1998; Oswald, 2008). Considering the conclusion of Oswald 
(2008, p. 22) (i.e. that ‘managers choose the correct method for accounting for 
R&D’), it is argued that the adoption of IAS 38 would remove a useful way 
companies use to communicate information (Stark, 2008). This argument is in line 
with Wyatt (2008) who suggests that giving management discretion ‘might facilitate 
more value relevant information on intangibles’ (ibid, p. 217). On that basis, one 
would expect implications in companies’ valuations because of the valuation of the 
R&D assets and expenses following the transition to IFRS.  
As a consequence, we perceive these arguments as a call for research of the 
subject matter. Hence, we explore the value relevance of the capitalised and the 
expensed portions of R&D (i.e. R&D assets and R&D expenses), separately. 
Considering that R&D expenses were treated as capital components in the UK (i.e. 
positively related to market values) in the past as well as the premise that assets are 
expected to bring future economic benefits, we expect that the capitalised portion of 
R&D has a positive relationship with market values. Instead, what remains as an 
expensed item should be negatively related to market values.10
H1: The capitalised as well as the expensed portions of R&D expenditure are 
value relevant in the UK, after 2005. (A positive (negative) and significant 
association between capitalized (expensed) R&D and market values is 
 Therefore, we test the 
following hypothesis: 
                                                 
10 Cazavan and Jeanjean (2006) argue that in the French context where capitalisation was optional 
(such as in the UK prior to 2005), R&D expense contained both unsuccessful and successful projects 
(due to the optional capitalisation). Moreover, the sign of R&D expense can ‘be negative or positive 
depending on the relative magnitude of unsuccessful and successful projects’ (ibid, p. 53). In the UK 
context after IFRS adoption, R&D expense would include unsuccessful projects (i.e. expenses 
unlikely to bring future economic benefits), therefore, resulting in a negative coefficient.   
 8 
 
A
ppendices 
expected.) 
Moreover, it is believed that large companies generate a larger portion of 
technological advancement (i.e. innovation) due to their size (cf. Cohen and Klepper, 
1992; Shah et al., 2008). Further, large firms are more effective in differentiating 
products or product lines with higher quality of innovations compared to smaller 
firms. Consistent with the above arguments, US studies (Chauvin and Hirschey, 
1993; Connolly and Hirschey, 2005) have indicated that firm size affects valuation. 
In particular, the effect of R&D on company value is greater for large firms over 
small firms suggesting size advantages regarding valuation, as a result of R&D 
expenditure. Against expectations, prior research in the UK reports no valuation 
differences of R&D for small and big firms (Shah et al., 2008; Shah et al., 2009).  
However, it is reminded that prior research is limited to valuation differences 
of R&D expenditure only, since capitalisation of R&D was rare in the UK prior to 
2005. On that basis, the actual amount that could be treated as an asset was not 
explicitly obvious to the users of the financial statements, limiting the illustration of 
the comparative advantage of large firms with regard to this issue. In fact, we argue 
that, because under IFRS the actual amount should be treated as a capital component 
becomes apparent in the financial statements (i.e. the expenditure meeting the 
criteria for capitalisation is actually capitalised rather than being included in the 
expensed portion), the valuation differences across large versus small companies will 
be significant. In particular, we expect any valuation implications of the capitalised 
as well as the expensed portions of R&D to be more prominent for large companies. 
Therefore, we test the following hypothesis:  
H2: There are different valuation effects of the R&D reporting between large and 
small companies in the UK, after 2005. (More (less) significant valuation 
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effects are expected for large (small) companies.) 
 
III. Methodology and Data  
Methodology 
A number in companies’ financial statements is deemed to be ‘value relevant’ if it is 
significantly related to its market value (Beaver, 2002). Following prior research 
(e.g. Shah et al., 2008; Oswald, 2008; Shah et al., 2009), in order to examine the 
value relevance of accounting information, we employ regression analysis by 
empirically implementing a theoretical extension of the fundamental Ohlson (1995) 
model where the market value of a firm can be expressed as a linear function of its 
book value of equity and net income.  In its simple form, the model is as follows: 
itititit NIaBVEaaMVE ε+++= 210       (1) 
 
where: 
o itMVE  is the market value of equity measured for the company i;  
o itBVE  is the book value of equity for company i for the respective year of 
observation (t);   
o itNI  is the net income for company i for the respective year of observation (t); 
o itε  is the mean zero disturbance term;  
 
Easton (1999, p. 402) highlights that one of the main advantages of the model 
is that ‘it forms a framework for understanding the relationship between prices and 
accounting data’. Another major advantage of this model is that the book value of 
equity and net income can be decomposed across different components, and hence 
examine the value relevance of individual items from a company’s financial 
statements, i.e. whether a particular accounting amount assists investors to value a 
company (Barth et al., 2001).  
On that basis and following prior research (Zhao, 2002; Han and Manry, 2004 
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Ahmed and Falk, 2006; Cazavan-Jeny and Jeanjean, 2006), we decompose BVE 
across the BVE before the capitalisation of R&D (hereafter ABVE) and the R&D 
assets (hereafter CapRD). Additionally, we decompose NI across the R&D expenses 
(hereafter ExpRD) and income before charging the R&D expenses (hereafter ANI). 
This results in Model (2). The coefficients of interest in this function are b2 and b4: 
 
itititititti ExpRDbANIbCapRDbABVEbbMVE ε+++++=+ 432103,              (2) 
where: 
o 3, +tiMVE  is the market value of equity measured three months after the year end 
for the company i;11
o 
  
itABVE is the adjusted book value of equity for company i for the respective 
year of observation (t), excluding the capitalised R&D investment;  
o itCapRD is the capitalised R&D amount, for company i for the respective year 
of observation (t); 
o itANI  is the adjusted earnings for company i for the respective year of 
observation (t), prior the R&D expense; 
o itExpRD  is the R&D expense, for company i for the respective year of 
observation (t); 
o itε  is the mean zero disturbance term;  
 
In order to address the second hypothesis, the sample is partitioned across the sub-
samples of large and small companies. As a benchmark for size, companies’ median 
market value with reference to the latest year of examination is used. Then, equation 
2 is run separately for each sub-sample. Additionally, similar to Shah et al. (2009), 
we introduce a dummy variable differentiating large from small companies in 
equation 2. This results in Equation (3) below. The coefficients of interest in this 
function are b5 and b9: 
 
                                                 
11 This ensures that the accounting information is in the public domain for some period and thus it has 
been ‘absorbed’ by investors (cf. Barth et al., 2008; Francis et al., 2004; Harris and Muller, 1999). 
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ititititit
ititititti
SExpRDbExpRDbSANIbANIb
SCapRDbCapRDbSABVEbABVEbSbbMVE
ε+++++
+++++=+
**
**
9876
5432103,
 
(3) 
where: 
o 3, +tiMVE  is the market value of equity measured three months after the year end 
for the company i;  
o S = 1 if the company is classified as large and = 0 otherwise; 
o itABVE is the adjusted book value of equity for company i for the respective 
year of observation (t), excluding the capitalised R&D investment;  
o SABVEit * is the adjusted book value of equity multiplied by the dummy 
variable  
o itCapRD is the capitalised R&D amount, for company i for the respective year 
of observation (t); 
o SCapRDit * is the capitalised portion of R&D multiplied by the dummy variable 
o itANI  is the adjusted earnings for company i for the respective year of 
observation (t), prior the R&D expense; 
o SANIit * is the adjusted earnings multiplied by the dummy variable 
o itExpRD  is the R&D expense, for company i for the respective year of 
observation (t); 
o SExpRDit * is the R&D expense multiplied by the dummy variable 
o itε  is the mean zero disturbance term;  
 
In order to control the models for heteroscedasticity, the ‘Heteroscedasticity-
consistent covariance matrix estimator 3’ (HC3) is employed. This method is 
suggested by McKinnon and White (1985) as producing more conservative 
confidence intervals than the basic method suggested by White (1980) and thus 
generating better results.  
For further reducing the possibility of heteroscedasticity the variables of the 
regression have been deflated by the number of shares (Barth and Clinch, 2009). The 
use of this deflator is consistent with the findings of Barth and Kallapur (1996) and 
Barth and Clinch (2009) suggesting that the number of outstanding shares is an 
effective proxy to capture the effect of scale. (As an alternative approach, we have 
also used the non deflated specification and the findings are economically similar.)  
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Moreover, we have also considered the issue of outliers by defining and 
excluding as outliers cases for which the standardised residuals lie outside the range 
of +/-2 standard deviations (Belsley et al., 1980). Finally, as we pool three years of 
data, we estimate all equations by clustering by year and industry (Petersen, 2009) to 
account for variations across the years and industries under examination (see below).  
 
Data 
In order to undertake the research, firms with ‘R&D activity’ should be identified. 
To identify such activity, we use the 2006 to 2008 UK R&D Scoreboards. The UK 
R&D Scoreboard is prepared annually by ranking the top 850 listed and non-listed 
companies (top 800 companies for 2006) undertaking R&D investment in the year 
before it gets published (DIUS, 2008).  
In order to perform the analyses, we exclude all the non-listed firms and all 
the firms listed in the AIM market. Therefore, the initial number of FTSE listed 
companies that are featured in the Scoreboards for the three years under examination 
is 726 firm year observations (311 firms). From those, 418 firm year observations 
have been used.12
 
 This sample consists of 214 observations with no R&D asset (i.e. 
expensers) and 204 observations with R&D asset (i.e. capitalisers). This provides a 
comparative advantage of our study over prior research  as a large number of the 
companies examined do capitalise R&D expenditure, allowing for statistically robust 
analyses regarding the capitalised portion of R&D. Table 1 below summarises the 
selection procedure of the sample. 
TABLE 1 – ABOUT HERE 
                                                 
12 83 observations regarding 2005, 169 observations regarding 2006 and 166 observations regarding 
2007.  
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Table 2 below details the number of observations across different industries 
(following the ICB industry classification) as well as the number of observations 
which are classified as ‘capitalisers’ and ‘expensers’. From this table, it becomes 
apparent that our sample is mainly consisted of firms in the ‘Industrials’, 
‘Technology’ and ‘Healthcare’ industries.  
 
TABLE 2 – ABOUT HERE 
 
Financial data are collected from Datastream and directly from the companies’ 
annual reports. More specifically, net income (NI) is the net income available to 
common equity defined as net income to calculate earnings per share (Worldscope 
item 01751). The book value of equity (BVE) is the common equity defined as the 
shareholders’ investment in a company (Worldscope item 03501). R&D expense is a 
Worldscope item (item 01201). Finally, considering that R&D asset in Worldscope 
is reported along with brands patents and other intangibles under the item ‘other 
intangible assets’, the R&D asset was hand collected from the companies’ annual 
reports for the respective year of observation. 
Tables 3 and 4 report the descriptive statistics for the full sample and the sub-
samples with regard to the variables used in this research.  
  
TABLE 3 – ABOUT HERE 
TABLE 4 – ABOUT HERE 
 
What really stands out from these descriptive statistics is that, relative to their 
size (i.e. scaled by the number of shares outstanding), large and small companies do 
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not invest significantly different amounts for R&D as one would expect (Chauvin 
and Hirschey, 1993). In fact, there is weak evidence that the capitalised portion of 
development expenditure is, on average, larger for small companies. Similar weak 
evidence is provided with regard to the amount expensed (judging by the median 
value). Although not tabulated, when deflating all variables by the value of total 
assets, the results are even more significant. Both the capitalised and the expensed 
portion of R&D are significantly larger for smaller firms (at 1%, both for the mean 
and the median values). 
 
IV. Results and Discussion 
The results of all tests are presented in Table 5. The findings regarding model (1) are 
consistent with prior research which examined the value relevance of accounting 
information in the UK prior to 2005 (e.g. King and Langli, 1998; Arce and Mora, 
2002). They indicate that accounting numbers in the UK have strong relationship 
with share prices (i.e., R2 is relatively high), the coefficient of book value of equity is 
close to its theoretical value (1) and the coefficient of net income is much higher.  
Moving into the results with regard to the decomposed model (2) for the 
pooled sample, as far as the variables of interest are concerned, it can be seen that the 
coefficient of CapRD is positive (3.280) and statistically significant at 1% level. 
Hence, it can be concluded that, consistent with our expectations, R&D asset is 
positively value relevant.  
This finding illustrates that investors perceive the capitalised portion of R&D 
expenditure as an asset with expected economic benefits when companies report 
under IFRS. Although this finding is consistent with prior research examining the 
value relevance of R&D either based on adjusted accounting figures (Lev and 
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Sougiannis, 1996; Healy et al., 2002; Lev et al., 2002) or actual accounting figures 
(Aboody and Lev, 1998; Zhao, 2002; Han and Manry, 2004; Ahmed and Falk, 2006) 
in other countries, it contradicts with the findings of Zhao (2002) who reports 
insignificant coefficients for the capitalised R&D portion by UK companies prior to 
2005. However, it is reminded that Zhao’s (2002) study was the only one to consider 
R&D assets separately from R&D expenses for UK companies prior to 2005. This, 
and the fact that very few companies capitalised R&D expenditure before 2005, 
indicates that our knowledge regarding the value relevance of capitalised R&D 
reporting prior to 2005 was limited.  
 Hence, it can be argued that the adoption of IFRS in the UK was not ‘a step 
in the wrong direction’ (cf. Ahmed and Falk, 2006, p. 238) since the reported R&D 
asset is (positively) value relevant under IFRS, In fact, it could be argued that this 
finding is in line with the expectations of Barth et al. (2008) and Ball (2006) that 
IFRS better reflect companies’ fundamentals and rejects the argument that the 
adoption of IFRS would hinder the value relevance of R&D reporting (cf. Stark, 
2008 and Wyatt, 2008).  
Focusing on the expensed portion of R&D (i.e. ExpRD), it can be seen that it 
is also statistically significant at 1% level but with a negative coefficient (-6.243), 
suggesting that the R&D expenses are negatively value relevant. This result is 
consistent with prior research (Zhao, 2002 (UK); Cazavan-Jeny and Jeanjean; 2006 
(France)) suggesting that the R&D expense is perceived by the market as 
unsuccessful projects with no economic benefits, contrary to the capitalised R&D 
portion.  
On that basis, our first hypothesis is supported. The capitalised as well as the 
expensed portions of R&D expenditure are positively and negatively value relevant 
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respectively in the UK, after 2005. 
 
TABLE 5 – ABOUT HERE 
 
The results with reference to the sub-samples, as presented in Table 5, shed more 
light with regard to our second hypothesis. More specifically, for both small and 
large companies, the coefficient of capitalised R&D is positive and significant (2.123 
and 4.973 respectively, at 10%). However, the difference between these two 
coefficients (2.850) is not significant. In contrast, the coefficient of R&D 
expenditure is significant only for large companies (at 1%). Additionally, it is 
significantly (at 1%) lower (by 9.396) than the corresponding coefficient of small 
companies.  
As robustness checks, we have also conducted all our analyses by following 
two steps regressions13
On that basis, we conclude that after the mandatory implementation of IFRS 
there are differences in the valuation of UK companies, with regard to R&D 
reporting because the expensed portion of R&D is consistently negatively value 
relevant only for large firms. This contrasts the findings of Shah et al. (2008) who 
 by introducing lagged market values, book-to-market and the 
percentage of foreign sales as instrumental variables. All the results are economically 
similar with exception being the results for model 3. In particular, we find the same 
signs for the differences in the coefficients of the capitalised and the expensed 
portion of R&D of both groups. However, we find significant the difference for the 
capitalised portion of R&D (at 10%) and insignificant the difference for the 
expensed portion. 
                                                 
13 We thank and anonymous reviewer for this suggestion. 
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find that R&D expense was significant (and positive) for both large and small 
companies prior to 2005. Nevertheless, in line with Shah et al. (2008), even after the 
adoption of IFRS, there is still no clear difference in the coefficients of this variable 
across the two sub-samples. Therefore, we conclude that the there is partial support 
for our second hypothesis.   
We argue that finding the R&D expense being negatively value relevant only 
for large firms, is a result of the adoption of IFRS which set more constraints on 
managers’ discretion regarding the capitalisation of the development expenditure. 
IFRS provide a clearer picture to investors on whether the research expenditure 
really constitutes expenditures on unsuccessful projects that will bring no future 
benefits to the company. As a result, investors can form better conclusions on 
whether the amounts spent on R&D are efficiently spent (i.e. if they are actually 
capitalised).  
More specifically, investors may expect larger companies to make more 
efficient use of the research expenditure because of economies of scale and scope 
(Chauvin and Hirschey, 1993) and to generate a larger portion of technological 
advancement (i.e. innovation) due to their size (cf. Cohen and Klepper, 1992; Shah 
et al., 2008). This would suggest size advantages with regard to their valuation as 
well. However, the descriptive statistics presented in table 4 indicate that, at least for 
our sample, there is no clear evidence that large companies invest and, as a result, 
capitalise more development expenditure, relative to their size. This results in the 
research expenditure to have negative effects on large companies’ market values 
only. This is interpreted as the large companies not having a valuation advantage 
because of the R&D they engage with.  
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V. Conclusion  
The subtle differences between UK GAAP and IFRS regarding the accounting 
treatment of R&D expenditure, along with evidence from Australia (cf. Wyatt, 
2008), have raised concerns with regard to the valuation implications of R&D 
reporting in the UK after 2005 (cf. Stark, 2008). Further, in contrast with evidence 
from the US, recent literature indicates that prior to 2005 there was ‘no clear-cut size 
[valuation] advantage of large firms over small firms’ as far as R&D was concerned 
in the UK (Shah et al., 2008, p. 90). Following along these lines, the present study 
examined whether the R&D reported assets and expenses are value relevant after the 
adoption of IFRS in the UK. Additionally, it examined any size-related valuation 
consequences of R&D after IFRS mandatory implementation in the UK.  
First, we find that, against the concerns that the adoption of IFRS may lead to 
less value relevant R&D reporting in the UK, during the first three years of IFRS 
mandatory implementation, the capitalised portion of R&D expenditure is positively 
value relevant. This was not the case under UK GAAP (cf. Zhao, 2002). Second, in 
contrast to the findings of Shah et al. (2008) regarding the pre-IFRS period, 
following the transition to IFRS there are size related valuation differences with 
reference to R&D expenditure in the UK. The expensed portion of R&D is 
significantly value relevant only for large companies.  
Considering our findings, we conclude that there is evidence supporting the 
expectations of Barth et al. (2008) and Ball (2006) that IFRS better reflect 
companies’ fundamentals. It remains an open path for future research to illustrate 
whether similar valuation implications, with regard to R&D reporting, hold in other 
countries where IFRS introduced different accounting treatment of the subject matter 
compared to the previously followed accounting regulations.   
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Table 1: Sample observations 
 No. of Observations 
Observations identified in the Scoreboards    2,500 
Observations of unlisted firms  (1,316) 
Observations of AIM listed firms  (457) 
Observations of OFEX listed firms  (1) 
Observations of FTSE listed firms     726 
Observations of financial companies         (41) 
Observations of companies not reporting under IFRS*  (118) 
Observations with missing data      (149) 
Final sample         418 
  
Firm year observations with R&D asset 204 
Firm year observations with no R&D asset 214 
*This refers to companies which adopted IFRS for their 2005/2006 financial statements, as a result of their 
yearend (e.g. end of April, March June etc). This is why we have substantially more observations for 2006.  
 
Table 2: Number of observations for each ICB industry 
ICB Industry N Percentage Capitalisers Percentage Expensers Percentage 
Oil & Gas 7 1.67% 0 0.00% 7 1.67% 
Basic Material 29 6.94% 7 1.76% 22 5.26% 
Industrials 146 34.93% 94 22.49% 52 12.44% 
Consumer Goods 44 10.53% 15 3.59% 29 6.94% 
Health Care 57 13.64% 26 6.22% 31 7.42% 
Consumer Services 26 6.22% 4 0.96% 22 5.26% 
Telecommunications 6 1.44% 3 0.72% 3 0.72% 
Utilities 14 3.35% 2 0.48% 12 2.87% 
Technology 89 21.29% 53 12.68% 36 8.61% 
Total 418 100% 204 48.80% 214 51.20% 
 
 
Table 3: Full sample descriptive statistics 
Variables N Mean Median SD Min Max 
MVE 418 3.69 2.05 4.92 0.01 52.33 
BVE 418 1.14 0.74 1.54 -1.30 12.51 
NI 418 0.19 0.10 0.45 -1.65 3.98 
ABVE 418 1.11 0.71 1.54 -1.33 12.51 
CapRD 418 0.03 0.00 0.07 0.00 0.78 
ANI 418 0.26 0.14 0.48 -1.55 3.99 
ExpRD 418 0.07 0.03 0.11 0.00 0.79 
NOSH (ml) 418 559 151 1,170 7.10 8,330 
All variables are deflated by the number of ordinary shares outstanding. MVE is the market value of equity 
measured three months after the year end, BVE is the book value of equity, NI is the net income, ABVE is the 
book value of equity excluding the R&D asset, CapRD is the R&D asset, ANI is the net income before the R&D 
expense, ExpRD is the expensed R&D and NOSH is the number of ordinary shares. 
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Table 4: Descriptive statistics of the sub-samples 
Variables N Mean Median SD Min Max 
  L S L S L S L S L S L S 
MVE 202 216 5.80 1.71 4.11 1.24 6.15 1.85 0.19 0.01 52.33 13.16 
test of difference   (0.000) (0.000)          
BVE 202 216 1.66 0.66 1.05 0.48 2.00 0.60 -0.37 -1.30 12.51 3.07 
test of difference   (0.000) (0.000)          
NI 202 216 0.37 0.02 0.20 0.03 0.56 0.20 -0.07 -1.65 3.98 0.51 
test of difference   (0.000) (0.000)          
ABVE 202 216 1.64 0.62 1.05 0.46 2.00 0.59 -0.37 -1.33 12.51 3.07 
test of difference   (0.000) (0.000)          
CapRD 202 216 0.02 0.04 0.00 0.00 0.07 0.07 0.00 0.00 0.78 0.41 
test of difference   (0.064) (0.000)          
ANI 202 216 0.45 0.09 0.26 0.07 0.60 0.22 -0.06 -1.55 3.99 0.99 
test of difference   (0.000) (0.000)          
ExpRD 202 216 0.08 0.07 0.03 0.04 0.14 0.08 0.00 0.00 0.79 0.63 
test of difference   (0.282) (0.018)          
NOSH (ml) 202 216 1,010 140 418 76.80 1,550 244 32.20 7.10 8,330 2,980 
test of difference     (0.000) (0.000)             
All variables are deflated by the number of ordinary shares outstanding. L represents the large firms whereas S 
represents the small firms. Test of difference is based on t-tests for the means and on Wilcoxon signed-ranks test 
for the medians, and their corresponding p-values are shown in brackets.  
MVE is the market value of equity measured three months after the year end, BVE is the book value of equity, 
NI is the net income, ABVE is the book value of equity excluding the R&D asset, CapRD is the R&D asset, 
ANI is the net income before the R&D expense, ExpRD is the expensed R&D and NOSH is the number of 
ordinary shares. 
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Table 5: Value relevance of R&D in the UK reporting after 2005  
(1) itititit NIaBVEaaMVE ε+++= 210  
(2) itititititti ExpRDbANIbCapRDbABVEbbMVE ε+++++=+ 432103,
 
(3) 
ititititit
ititititti
SExpRDbExpRDbSANIbANIb
SCapRDbCapRDbSABVEbABVEbSbbMVE
ε+++++
+++++=+
**
**
9876
5432103,  
Variables 
Pooled sample Sub-samples Difference  
(Model 3) Basic 
Model (1) 
Decomposed 
Model (2) 
Small 
firms 
Large  
firms 
Intercept 0.929*** 0.809*** 0.558 1.065*** 0.507** 
BVE 1.031***     
NI 7.538***     
ABVE  0.940*** 0.957*** 0.541*** -0.416 
CapRD  3.280*** 2.123* 4.973* 2.850 
ANI  7.861*** 4.480*** 10.326*** 5.846*** 
ExpRD  -6.243*** -0.695 -10.090*** -9.395*** 
F 221.83*** 116.30*** 189.38*** 173.61***  
Adj R2 0.72 0.73 0.54 0.77  
N 378 378 210 168   
***, ** and * indicate statistical significance at the 1%, 5% and 10% levels, respectively 
All variables are deflated by the number of ordinary shares outstanding. BVE is the book value of equity, NI is 
the net income, ABVE is the book value of equity excluding the R&D asset, CapRD is the R&D asset, ANI is 
the net income before the R&D expense, ExpRD is the expensed R&D and S is the dummy variable for size: 
where S = 1 if the company is classified as large and = 0 otherwise. 
 
 
